Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 25 January 2018

Indication(s)

COMETRIQ is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Load more

Related Content

Journal articles

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer.

Until recently, there had not been an effective systemic chemotherapy for advanced differentiated thyroid carcinoma (DTC); lenvatinib, a multi-tyrosine kinase inhibitor, has been proven effective for DTC...

Added 1 year ago

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.

Introduction: Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poor effective. Several TKIs have been tested in clinical trials in pMTC patients.

Added 1 year ago

Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.

Background: The objective of the study was to reveal through pragmatic MCDA (EVIDEM) the contribution of a broad range of criteria to the value of the orphan drug lenvatinib for radioiodine refractory ...

Added 1 year ago

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.

Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1-3...

Added 1 year ago

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1...

Added 4 years ago

Load more

View all 12845 Journal articles items
Guidelines

European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS

Thyroid ultrasound (US) is a key examination for the management of thyroid nodules. Thyroid US is easily accessible, noninvasive, and cost-effective, and is a mandatory step in the workup of thyroid nodules.

Added 7 months ago

Guidelines for the management of thyroid cancer

The intention is to provide guidance for all those involved in the management of patients with differentiated thyroid cancer (DTC) and some of the rarer thyroid cancers.

Added 4 years ago

2013 European Thyroid Association Guidelines for Cervical Ultrasound Scan and Ultrasound-Guided Techniques in the Postoperative Management of Patients with Thyroid Cancer

The main aim is to establish guidelines for both a cervical US scanning protocol and US-guided diagnostic and therapeutic procedures in patients with thyroid cancer.

Added 5 years ago

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

This guideline covers incidence and epidemiology, diagnosis, staging and management of differentiated thyroid cancer, medullary thyroid cancer, poorly differentiated thyroid carcinoma and anaplastic thyroid cancer.

Added 6 years ago

Load more

View all 1443 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/002640
Orphan designation Yes
Date First Approved 21-03-2014
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder

Ipsen Pharma
Warnings

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti